The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients.
Christoph Eichhorn
No relevant relationships to disclose
Max Schlaak
Honoraria - Bristol-Myers Squibb
Jessica C. Hassel
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Carmen Loquai
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Roche
Honoraria - Bristol-Myers Squibb; Roche
Other Remuneration - Bristol-Myers Squibb; LEO Pharma; Merck Sharp & Dohme; Roche
Ingo Stoffels
No relevant relationships to disclose
Ralf Gutzmer
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis
Honoraria - Amgen; GlaxoSmithKline; Merck Serono; Merck Sharp & Dohme; Roche
Research Funding - Novartis; Roche
Other Remuneration - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
Sylvie Paetzold
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Ulrich Keller
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Jens Ulrich
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Athanasios Tsianakas
No relevant relationships to disclose
Friederike Egberts
No relevant relationships to disclose
Eva Janssen
No relevant relationships to disclose
Claus Garbe
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; LEO Pharma; Merck Sharp & Dohme; Philogen; Roche
Honoraria - Roche
Thomas K. Eigentler
Consultant or Advisory Role - Bristol-Myers Squibb; LEO Pharma; Philogen
Honoraria - Bristol-Myers Squibb; Roche